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ABSTRACT
The secretion of soluble pro-angiogenic factors by tumor cells and stromal cells 
in the perivascular niche promotes the aggressive angiogenesis that is typical of 
glioblastoma (GBM). Here, we show that angiogenesis also can be promoted by a 
direct interaction between brain tumor cells, including tumor cells with cancer stem-
like properties (CSCs), and endothelial cells (ECs). As shown in vitro, this direct 
interaction is mediated by binding of integrin avβ3 expressed on ECs to the RGD-
peptide in L1CAM expressed on CSCs. It promotes both EC network formation and 
enhances directed migration toward basic fibroblast growth factor. Activation of αvβ3 
and bone marrow tyrosine kinase on chromosome X (BMX) is required for migration 
stimulated by direct binding but not for migration stimulated by soluble factors. RGD-
peptide treatment of mice with established intracerebral GBM xenografts significantly 
reduced the percentage of Sox2-positive tumor cells and CSCs in close proximity 
to ECs, decreased integrin avβ3 and BMX activation and p130CAS phosphorylation 
in the ECs, and reduced the vessel surface area. These results reveal a previously 
unrecognized aspect of the regulation of angiogenesis in GBM that can impact 
therapeutic anti-angiogenic targeting.
INTRODUCTION
A highly angiogenic phenotype is a distinctive 
feature of glioblastoma (GBM), and is thought to 
contribute to the aggressive growth, invasive phenotype 
and post-therapy recurrence of these tumors [1–3]. 
In GBM and other cancers, pro-angiogenic signaling 
molecules, including basic fibroblast growth factor 
(bFGF) and vascular endothelial growth factor A 
(VEGF-A), are secreted by stromal cells and tumor 
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cells. These factors promote endothelial (EC) activation, 
survival, protease secretion, sprouting and migration [2–
5]. Our understanding of how the angiogenic process 
is regulated is not complete, however; for example, 
regulation of VEGF-induced sprouting in ECs by 
metabolic pathways was shown recently [6].
The migration of ECs towards paracrine-acting 
pro-angiogenic factors is mediated by integrins in 
cooperation with growth factors/growth factor receptors 
[7, reviewed in [8–10]]. Cell surface-expressed integrins 
recognize and are activated by ligands typically localized 
in the extracellular environment. This activation, in 
turn, results in activation of cytoplasmic kinases, 
such as Src and focal adhesion kinase (FAK), as well 
as adaptor molecules, such as p130CAS, resulting in 
reorganization of the actin cytoskeleton and generation 
of the mechanical force needed to pull the cell forward 
[7–12]. Several integrins recognize an RGD-peptide 
in their ligands. Cell adhesion receptors other than 
integrins, including L1CAM, also can promote cell 
migration [reviewed in [13]]. L1CAM binds to RGD-
peptide-binding integrins, including integrin αvβ3 due to 
the presence of an RGD-peptide in its extracellular sixth 
Ig domain and this peptide appears to be necessary for 
the pro-migratory and pro-invasive effects of L1CAM in 
cancer cells [13–18].
In malignant tumors, a specialized perivascular 
microenvironment has been identified in which cancer 
stem-like cells (CSC) reside in very close proximity 
to ECs [19]. Use of integrin α6 as a marker of CSCs 
indicates that approximately 60% of integrin α6-
positive cells reside within 5-µm of blood vessels in 
GBM [20]. It has been suggested that ECs maintain the 
CSC population, promoting the survival of the CSCs 
through secreted soluble factors (e.g., nitric oxide) and 
laminin-α2 [20–23]. Conversely, the CSCs affect the 
ECs and promote angiogenesis through secretion of pro-
angiogenic factors [4, 5]. There is some evidence that 
CSCs may interact directly with ECs; medulloblastoma 
CSCs bind to ECs plated on Matrigel® and promote EC 
network formation [19] and melanoma cell contact with 
ECs in serum-containing media promotes expression 
of genes that regulate cancer cell migration and tumor 
progression [24]. Neither of these studies addressed 
the question of the mechanisms underlying the 
interactions or the identity of the cell type expressing 
the upregulated genes. Thus, the possibility that CSCs 
interact directly with ECs in the perivascular niche and 
affect EC behavior remains largely unexplored. We have 
examined direct interactions between primary brain 
ECs and CSCs derived from GBM or GBM cell lines 
and the subsequent signaling events using both in vitro 
approaches and an in vivo mouse model of GBM.
RESULTS
Direct contact of ECs and CSCs involving cell-
cell adhesion mediated by integrin αvβ3 on ECs 
and L1CAM on CSCs
Using a cell-cell adhesion assay, we found that the 
CSCs readily adhere/bind to a confluent monolayer of ECs 
plated on collagen and that 4-fold more CSCs adhered/
bound to ECs than to astrocytes (Figure 1A, SFigure 1A).
Integrin αvβ3, an RGD peptide-binding integrin 
that promotes EC adhesion, migration and survival 
[reviewed in [8, 9]], is upregulated on tumor-associated 
ECs in GBM biopsies [25]. The expression of the cell 
adhesion molecule L1CAM that contains an RGD-peptide 
is increased on CSCs from GBM [26]. Immunoblotting 
confirmed expression of the integrin β3 subunit on ECs and 
expression of L1CAM on CSCs (Figure 1B). An antibody 
that blocks integrin binding to the RGD peptide in L1CAM 
[14, 27] reduced CSC adhesion to ECs (Figure 1A). Pre-
incubation of ECs with a neutralizing antibody to integrin 
αvβ3 or αvβ5 significantly reduced CSC adhesion to ECs 
(43% and 10%, respectively), but pre-incubation with a 
neutralizing antibody to α5β1 did not (Figure 1A&1C). As 
anti-integrin αvβ3 and anti-L1CAM in combination did not 
further inhibit CSC adhesion to ECs, integrin αvβ3 is most 
likely the major integrin involved in mediating this adhesion 
(Figure 1A). A cyclic-RGD-peptide significantly inhibited 
CSC adhesion to ECs in a concentration-dependent manner 
whereas a control RAD-peptide did not (Figure 1D). 
Downregulation of either the integrin β3 subunit on ECs 
or L1CAM on CSCs using pooled siRNA significantly 
inhibited CSC adhesion to ECs (Figure 1E). Similarly, 
downregulation of either the integrin β3 subunit on ECs or 
L1CAM on CSCs using two different single-target siRNAs 
for integrin β3 and two different single target-siRNAs 
for L1CAM significantly inhibited CSC adhesion to ECs 
(Figure 1F&1G). Moreover, overexpression of L1CAM in 
U-118 MG GBM cells (L1LE) [28] promoted the binding 
of GBM cells to ECs as compared to U-118 MG cells 
expressing the vector control (Figure 1H) and the expression 
of L1CAM on the 08387 CSCs promoted increased binding 
of CSCs to ECs as compared to the paired 08387 non-stem 
tumor cells (NSTCs) (SFigure 1B).
CSCs from GBM promote network formation 
by brain ECs, activation of integrin αvβ3 and 
phenotypic changes in ECs
On co-seeding primary brain ECs with CSCs on 
Matrigel®, an interaction between ECs and CSCs could 
be seen at 2 h (SFigure 1C). The number of EC segments/
branches (network formation) was higher on co-seeding 
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of CSCs with ECs than when ECs were seeded in CSC-
conditioned media (CM) (Figure 1I). This significantly 
higher number of segments/branches on co-seeding 
of CSCs with ECs than when ECs were seeded in CM 
(ECs+CSCs) was observed when the ECs were pre-seeded 
at 2, 4, or 18 h prior to the addition of CM (ECs+CSCs) 
or CSCs (Figure 1J).Thus, in subsequent experiments 
we differentiated the effects of direct contact to those of 
Figure 1: Integrin αvβ3 on ECs and L1CAM on CSCs mediate the direct contact of ECs and CSCs. A-H. CSC adhesion 
measured by plating of GFP-CSCs-(08387) (3x104) over unlabeled-ECs or astrocytes (5x104/well) that had been seeded in serum-free 
adhesion assay buffer on plates coated with 10 µg/mL collagen. The GFP-CSCs-(08387) were incubated with the ECs or astrocytes (30 
min), washed 3X with PBS and CSC adhesion to the EC or astrocyte monolayer measured by detection of GFP-CSC fluorescence using a 
fluorometer (485nm absorption, 535 nm emission) (replicates of five). (A-D) In some experiments, after overnight attachment, the seeded 
ECs or astrocytes were incubated with blocking antibody (A, C) or RGD peptide (D) or the corresponding controls for 30 min and the CSCs 
were incubated with blocking antibody (A, C) or RGD peptide (D) or the corresponding controls (30 min) prior to plating the CSCs over 
the EC or astrocyte monolayer. Expression of integrin β3 and L1CAM on adherent ECs and CSCs was determined by immunoblotting (B). 
(E-H) In some experiments, the ECs or CSCs were pretreated with pooled siRNA to β3 or L1CAM for 48h (E); or single target siRNA to 
L1CAM for72 h (F) or β3 for 72h (G); or adhesion of L1CAM overexpressing (L1LE) cells and U-118 MG cell vector control (K1879) to 
an EC monolayer was measured (H). I–J. Network/branch formation quantified as the number of segments/branches at 24 h after seeding 
of red-fluorescent ECs (20,000) alone or mixed with GFP-CSCs (20,000) or with astrocytes (20,000) onto Matrigel® in complete NBM (I) 
or after seeding onto Matrigel® in complete NBM 2, 4, or 18 h prior to the addition of CM (ECs+CSCs) or CSCs (J). Statistics: A, C, E-I, 
two-sided exact Wilcoxon rank-sum tests; D, two-way ANOVA; and J, repeated measure ANOVA. Graphs: A & I, Box and Whisker plots, 
C, E-H, data plotted as bar graphs, mean±SEM.
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soluble factors by comparing the effects of co-seeding to 
the effects of CM.
For the subsequent experiments, we used laminin 
as the substrate as CSCs from GBM retain their stem 
cell phenotype when plated on laminin in neural basal 
media (NBM) [29] and integrin α6β1 mediates brain EC 
attachment to laminin [30].
To determine whether the direct contact activates 
ECs, we analyzed mRNA levels of two markers of 
EC activation using qRT-PCR. The results indicated 
significantly higher E-selectin and VCAM-1 mRNA 
levels (9-fold and 34-fold, respectively) in ECs that 
were co-seeded with CSCs than in ECs seeded in CM 
obtained from co-seeded ECs and CSCs (CM/EC+CSC) 
at 3 h, indicating that EC activation was not induced by a 
secreted factor at this time point (Figure 2A).
Addition of recombinant L1CAM to ECs seeded 
alone resulted in activation of integrin αvβ3, as assessed 
by staining for phospho-β3 (pY759) [31, 32], confirming 
that integrin αvβ3 can be activated upon binding L1CAM 
(Figure 2B). The growth factor bFGF is upregulated in 
GBM; thus, to determine whether integrin αvβ3 on ECs is 
activated on binding L1CAM on CSCs, we co-seeded ECs 
and CSCs on laminin in the presence of bFGF (3 h) using 
Sox2 as a positive control for CSCs [33]. A significant 
increase in integrin β3 phosphorylation was observed 
when ECs were co-seeded with CSCs (Figure 2B).
Co-seeding of ECs with CSCs resulted in a 
phenotypic change in the ECs (Figure 2C). The number 
of ECs with stress fibers was significantly lower and 
the number with cortical actin was significantly higher 
as compared to ECs seeded in CM/EC+CSC (Figure 
2C&2D). This suggested induction of a pro-migratory 
phenotype in the ECs on co-seeding with CSCs. As the 
phosphorylation of early downstream signaling effectors 
FAK and p130CAS is dynamic and depends on an 
organized actin cytoskeleton [reviewed in [8–10]], we 
quantitated the intensity of p130CAS phosphorylation 
(pY234) in confocal stacks of ECs. In ECs co-seeded 
with CSCs, phospho-p130CAS-(pY234) was nearly 
3-fold higher than in ECs seeded in CM/EC+CSC (Figure 
2E&2F); however, there was no significant difference 
in total p130CAS in ECs co-seeded with CSCs versus 
ECs seeded alone in CM/EC+CSC, based on cell harvest 
with Accutase, sorting for CD31, cell lysis and blotting 
for p130CAS (Figure 2F). FAK activity (pY397) was 
similarly increased in the ECs co-seeded with CSCs, 
as compared to ECs seeded in CM/EC+CSC (data not 
shown). Double-labeling for phosphorylated p130CAS 
and actin (Alexa-594-Phalloidin) followed by confocal 
microscopy showed focal co-localization at the membrane 
in ECs co-seeded with CSCs (Figure 3A). The downstream 
effectors ERK and JNK also can promote cell migration 
[34]. The activation of ERK and JNK was significantly 
higher in ECs co-seeded with CSCs from four different 
GBM tumors as compared to ECs seeded in CM/EC+CSC, 
and this increase was blocked by addition of RGD peptide 
(Figure 3B-3D; SFigure 2A). Collectively, these results 
suggest that the direct interaction between CSCs and 
ECs might represent a pro-angiogenic behavior of ECs 
as indicated by network formation and a transition in the 
ECs from a quiescent phenotype to an activated, migratory 
phenotype.
CSCs increase the motility of ECs through direct 
contact as well as secreted factors
We investigated the effect of CSCs on EC migration 
using a 2D cell motility assay in which ECs and CSCs 
were seeded in NBM on laminin on either side of a 
500-µm gap, and migration assessed over 24 h by live-
imaging (Figure 4A). EC migration was almost completely 
inhibited by a neutralizing anti-integrin α6 antibody 
(Figure 4B). As compared to positioning of CSCs or ECs 
on both sides of the gap, the positioning of CSCs opposite 
ECs (on either side of the gap) significantly increased 
EC and CSC migration into the gap (10- and 14-fold, 
respectively; Figure 4C; SFigure 2B). Moreover, by 24 h 
the cells had filled the gap, whereas at this time point only 
35% of the gap was filled when either CSCs or ECs were 
plated on both sides.
Live video imaging showed that contact between the 
ECs and CSCs first occurred after 7 h in this assay (Figure 
4H); thus, the effects of potential CSC-secreted factors 
in the absence of direct contact could be assessed during 
the first 7 h. On tracing the paths of 30 ECs, we found 
that in the absence of CSCs (-CSCs), the ECs migrated 
randomly whereas when CSCs were present the majority 
of ECs displayed a preferential migration in the direction 
of the CSCs (negative X axis) (Figure 4D; SFigure 2C). 
During the first 7 h, there was no significant difference 
in the velocity of the ECs when plated opposite CSCs or 
ECs (Figure 4F).Thus, potentially, CSC-secreted factors 
promote the directional motility of ECs but do not alter 
the velocity.
We then assessed the effects of direct contact of 
CSCs with ECs on EC migration by tracing trajectories 
during the 7-24 h time frame. We compared the trajectories 
of 30 ECs that had been observed to make contact with 
CSCs during the 7-24 h time frame with the trajectories 
of 30 ECs that never contacted CSCs but were plated 
opposite of CSCs, over the same time frame. We found 
that the ECs that had been observed to contact CSCs 
exhibited a significantly greater displacement and velocity 
(21.3 µm and 0.3 µm/min, respectively), and exhibited 
directional migration, compared to the ECs that had never 
contacted CSCs (3.4 μm and 0.23 µm/min, respectively) 
(Figure 4E&4G; SFigure 2D). ECs that were seeded in the 
absence of CSCs continued to display random migration 
(SFigure 2E).
To assess the effect of EC-CSC contact on EC 
migration towards a chemo-attractant, we used a 
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Transwell® assay with laminin-coated 3-μm pore filters to 
mimic the tight spaces in the brain extracellular matrix 
[35] (Figure 5A). Red-fluorescent-ECs were mixed, co-
seeded with GFP-CSCs in the upper chamber and allowed 
to migrate for 6 h towards bFGF in NBM in the bottom 
chamber. Co-seeding of ECs with CSCs in the top chamber 
significantly increased EC migration as compared to 
migration of ECs seeded alone in the top chamber (Figure 
5B). The increase in EC migration when co-seeded with 
CSCs was not replicated by seeding ECs in CM/EC+CSC, 
indicating the increase in EC migration was not due to a 
secreted factor(s) (Figure 5C).
Figure 2: The direct interaction of ECs and CSCs activates ECs and promotes activation of integrin αvβ3 and p130CAS 
in ECs. A. mRNA levels of genes marking EC activation were measured by qRT-PCR analysis of ECs seeded onto laminin in CM/
EC+CSC (in growth-factor-free NBM) or mixed directly with CSCs-(08387) (growth-factor-free NBM) for 3 h (37°C, 5% CO2). ECs were 
then isolated by sorting for CD31. mRNA levels of genes after normalization to GAPDH are shown. B-F. Immunofluorescent analysis of 
markers of activation and signaling in ECs. ECs in CM/EC+CSC (growth factor-free NBM + 10 ng/ml bFGF) or mixed directly with CSCs 
(growth factor-free NBM + bFGF) were seeded onto laminin (3 h). Representative photomicrographs and quantification of phospho-β3 
(Y759), a marker of integrin αvβ3 activation; white arrows denote phospho-β3 and yellow arrows denote CSCs (B); phalloidin-Alexa-594 
(binds actin) and vWf (Alexa-647-yellow); arrows denote ECs with cortical actin or vWf expression (C-D); phosphorylated p130CAS 
(phos-p130CAS Y234; Alexa-488, green) and vWf (magenta); white arrows, green phos-p130CAS; and yellow arrows, CSCs (E). The 
intensity of green signal calculated using FIJI (ImageJ) based on the sum of the mean gray level (intensity) output of all pixels of the area 
within the enclosed cell traced along its outer edge, for each confocal section taken at 0.5 µm steps comprising the Z-stack. Signal intensity 
was normalized by dividing the sum of the mean gray level by the area of the cell. (F). Statistics: A, B, D and F, two-sided exact Wilcoxon 
rank-sum tests; data plotted as mean±SEM.
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Src phosphorylates the substrate domain of 
p130CAS, which is necessary for p130CAS activation 
[reviewed in [8–10]]. Preincubation of ECs with the Src 
inhibitor 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)
pyrazolo[3,4-α]pyrimidine (PP2) for 20 min followed by 
washing and seeding significantly inhibited EC migration 
towards bFGF whether the treated ECs were co-seeded 
with CSCs or seeded alone (Figure 5B). Downregulation 
of β3 in ECs resulted in a significant decrease in migration 
of ECs co-seeded with CSCs (Figure 5D), but had no 
significant effect on the migration of ECs that were 
seeded alone (Figure 5D). This was consistent with our 
observation that integrin αvβ3 is not mediating adhesion 
or migration of ECs on laminin. Downregulation of 
L1CAM on CSCs also resulted in a significant reduction 
in migration of ECs co-seeded with CSCs (Figure 5E).
Collectively, these data suggest that the interaction of 
CSCs with ECs activates signaling effectors in ECs 
thereby promoting migration towards bFGF that is not 
mediated by binding of integrin αvβ3 to the laminin 
substrate.
Figure 3: The direct interaction of ECs and CSCs activates ERK and JNK in ECs in an RGD-peptide-dependent 
manner. ECs were seeded alone or with CSCs as in Figure 2B and markers detected by immunofluorecent labeling followed by confocal 
microscopy. A. Phosphorylated p130CAS (Y234) (Alexa-488, green) and actin (Alexa-594-Phalloidin, red). Sections comprising the 
Z-stack shown; white arrowheads-actin stress fibers; white arrows-co-localization (yellow) of phos-p130CAS and actin at membrane; 
and yellow arrows-CSCs. B. Phospho-ERK or phospho-JNK (Alexa-594, red) and vWf (Alexa-647, magenta). White arrows denote vWf-
positive ECs expressing pERK or pJNK; and yellow arrows denote GFP-CSCs-(08387). C. RGD- or RAD-peptide (50 µM) were incubated 
with cells during seeding. D. ECs co-seeded with a second CSC isolate (4302) or in CM/EC+CSC; fluorescent intensity analyzed in 50 ECs 
and graphed as the fold-change. Statistics: B and C, two-sided student t-tests and D, two-sided Wilcoxon rank-sum test; B-D, Fold change 
in pERK or pJNK graphed as the mean±SEM.
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Bone marrow tyrosine kinase on chromosome 
X (BMX) as well as FAK and p130CAS are 
required for enhanced migration of ECs towards 
bFGF when co-seeded with CSCs
To determine whether p130CAS was necessary 
for the enhanced migration of ECs when co-seeded with 
CSCs, we downregulated p130CAS in the ECs with 
two different single target siRNAs or pooled p130CAS 
siRNA (Figure 5F, SFigure 3A). This resulted in a 
significant inhibition of EC migration towards bFGF 
when co-seeded with CSCs or when seeded in CM/
EC+CSC (Figure 5G, SFig 3B). Both FAK and BMX can 
phosphorylate p130CAS, although at different sites, and 
contribute to p130CAS activation [8-10, 36]. When FAK 
was downregulated in the ECs, we found a significant 
inhibition of EC migration whether the ECs were co-
seeded with CSCs or seeded in CM/EC+CSC (Figure 
5F&5H). In contrast, when BMX was downregulated in 
the ECs we found a significant inhibition of EC migration 
when the ECs were co-seeded with CSCs, but not when 
they were seeded alone in CM/EC+CSC (Figure 5F&5H). 
Supporting these findings, the use of a FAK or a BMX 
inhibitor (1µM) showed highly similar effects on EC 
Figure 4: CSCs increase the directional 2D motility of ECs through both secreted factors and direct contact. A. EC 
migration is mediated by an α6 integrin. Cell culture inserts were coated with 20µg/mL laminin, and red-fluorescent-ECs (30,000, EGM 
media) were plated on one side of the insert, and GFP-CSCs-(08387) (30,000, complete NBM) on the other side. At 18 h, all media were 
replaced with complete NBM; the insert removed, and live-imaging performed q 15 min (24 h, 37°C, 5% CO2). Migration was measured 
by counting each fluorophore in an automated fashion (customized software). B. In certain experiments, blocking anti-integrin α6 antibody 
or IgG as a control (5 µg/ml) was included in the complete NBM and nearly completely inhibited EC migration towards CSCs. C. Plot of 
gap closure. D. Paths of 30 ECs were manually traced in the first 7 h before EC-CSC contact and E. between 7-24 h when EC-CSC contact 
occurs using Manual Tracker (Image J). The final destination of each EC denoted on the graph, mean overall displacement-Euclidean 
distance (all 30 ECs) shown with the arrow. F. Mean EC velocity (displacement/time-µm/min) graphed as a bar graph of the mean±SEM 
or G. as Box and Whisker plots. H. Examples of ECs contacting CSCs in the gap area at various time points after 7 h; white arrows-ECs, 
yellow arrows-CSCs, and black arrowhead-point of EC-CSC contact. Statistics: C, F, and G, two-sided exact Wilcoxon rank-sum tests.
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migration as compared to downregulation of FAK or 
BMX expression, respectively (Figure 5I). This indicates 
a differential requirement for BMX for the increased 
chemotactic migration of ECs when they are co-seeded 
with CSCs.
We therefore determined whether BMX was 
necessary for p130CAS activation in ECs co-seeded with 
CSCs, by downregulating BMX in ECs that were then 
co-seeded with CSCs on laminin in NBM with bFGF (3 
h). The downregulation of BMX significantly inhibited 
Figure 5: The direct interaction of ECs and CSCs promotes EC migration towards bFGF. A. Diagrammatic representation 
of experimental design. Filters (3-µm pore) were coated on both sides with 20 µg/mL laminin. Red-fluorescent-ECs (3x104) were seeded 
alone or mixed with GFP-CSCs-(08387) (3x104) and co-seeded in growth factor-free NBM with 1% BSA on top of the filter. Growth 
factor-free NBM with 10 ng/ml bFGF was placed in the bottom chamber, and the cells allowed to migrate (37°C, 5% CO2). At 6 h, cells 
were removed from the upper filter surface and cells on the lower filter surface were washed, fixed, photographed and quantified. B. The 
Src inhibitor PP2 (1 µM) was incubated with ECs (20 min), followed by washing, and EC seeding alone or co-seeding with CSCs. C. 
ECs were seeded in CM/EC+CSC (described in Figure 2B), or co-seeded with CSCs. D, E. ECs were treated with integrin β3 specific 
siRNA, L1CAM specific siRNA or with control siRNA for 48 h, washed and seeded alone or with GFP-CSCs. F-H. Downregulation by 
the indicated siRNA or control siRNA (48 h FAK and BMX, 72 h p130CAS) in ECs was confirmed by immunoblotting (F), then ECs were 
treated with p130CAS, FAK or BMX specific siRNA or with control siRNA, washed and seeded alone or with GFP-CSCs. I. ECs were 
treated with 1µM of the FAK or BMX inhibitor or DMSO (control), washed and seeded alone or with GFP-CSCs. Statistics: B-E, G-I, two-
sided exact Wilcoxon rank-sum tests, and data graphed as the mean±SEM.
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p130CAS phosphorylation in ECs co-seeded with CSCs 
but had no effect on p130CAS phosphorylation in ECs 
seeded alone in CM/EC+CSC (Figure 6A&6B). To 
determine whether BMX was activated in ECs on co-
seeding with CSCs, phospho-BMX was detected by 
immunofluorescence and fluorescent intensity quantitated 
as described for phospho-p130CAS. We found a 
significant increase (~3-fold) in phospho-BMX in ECs 
co-seeded with CSCs as compared to ECs seeded alone 
in CM/EC+CSC (Figure 6C&6F) although there was no 
significant difference in total BMX in ECs in the two 
conditions after Accutase harvest, CD31 sorting, lysis 
and blotting for BMX (Figure 6E). To further determine 
whether the increase in phospho-BMX was dependent 
on integrin αvβ3 in the ECs co-seeded with CSCs, we 
downregulated the β3 subunit in ECs. There was a 
significant inhibition of BMX phosphorylation in the ECs 
in which the β3 subunit was downregulated when they 
were co-seeded with CSCs, but the BMX phosphorylation 
in these ECs was unaffected when they were seeded alone 
in CM/EC+CSC (Figure 6C, 6D&6F). Taken together, 
these data indicate that BMX is necessary for the increased 
p130CAS activation and EC migration towards bFGF in 
ECs co-seeded with CSCs on laminin, but is not necessary 
for p130CAS activation and EC migration when ECs are 
seeded alone.
RGD-peptide treatment reduces the proximity of 
Sox2-positive tumor cells to ECs and decreases 
phosphorylation of BMX and p130CAS in ECs 
in a xenograft model of GBM
Others have reported that cyclic-RGD-peptide 
(Cilengitide) treatment prolongs survival of scid mice 
bearing intracerebral GBM tumors, and of nude rats 
bearing intracerebral GBM tumors when administered 
with radiation [37, 38]. As we had found that an RGD-
peptide blocks the interaction of integrin αvβ3 on ECs 
with L1CAM on CSCs, we examined the effects of 
administration of the cyclic-RGD-peptide in an established 
orthotopic mouse model of GBM on the distance of 
Sox2-positive tumor cells from ECs and integrin αvβ3-
mediated signaling in the ECs. LN-308 GBM cells were 
utilized as they express L1CAM when propagated as 
neurospheres in NBM (Figure 7A), bind to ECs in the 
cell-cell adhesion assay in an L1CAM-dependent manner 
(Figure 7B), and promote EC migration towards bFGF in 
an L1CAM-dependent manner (Figure 7C&7D). LN-308 
cells were injected into the nude mouse brain and at day 
55 administration of cyclic RGD-peptide was initiated, 
followed by euthanasia and brain harvest on day 60. We 
found a significant increase in the mean distance of Sox2-
positive cells from ECs (Figure 7E&7F), and a significant 
decrease in the number of Sox2-positive cells within 25-
µm of blood vessels (Figure 7F&7G). Also, we found 
significant decreases in the percent of ECs expressing 
pβ3-(Y759), in the intensity of phospho-BMX (BMX 
activation) and phospho-p130CAS in ECs, and in vessel 
surface area in the tumors of RGD-peptide treated mice as 
compared to controls (Figure 7F, 7H-7K). Phospho-BMX 
staining of ECs in the xenograft tumors was detected in 
a population of vessels, consistent with BMX expression 
in vessels of arterial origin [39, 40]. These data suggest 
that ECs interact with tumor cells in the perivascular 
niche through an RGD-peptide-binding integrin and that 
this interaction promotes BMX and p130CAS activation, 
thereby enhancing angiogenesis.
DISCUSSION
Here, we describe for the first time a direct 
interaction of ECs with CSCs from GBM that is mediated 
through binding of integrin αvβ3 on ECs to the RGD-
peptide in the extracellular domain of L1CAM on CSCs. 
This activates integrin αvβ3 on ECs and, in the presence 
of bFGF, results in significantly increased activation 
of BMX, FAK and p130CAS, increased activation of 
the downstream effectors ERK and JNK, and marked 
changes in the phenotype of the ECs. Importantly, this 
level of upstream and downstream effector activation 
was not achieved by EC seeding in CM/EC+CSC with 
bFGF, indicating that it cannot be attributed to a secreted 
factor(s). Furthermore, the increase in ERK and JNK 
activation was RGD-peptide-dependent suggesting a 
requirement for the direct interaction of ECs with CSCs 
rather than an effect due to integrin α6-mediated adhesion 
to laminin (which is RGD-peptide-independent) [reviewed 
in [8, 9]]. Minimal p130CAS activation was detected 
in CSCs, suggesting activation of another p130CAS 
family member, such as NEDD9(HEF1) [12, 41]. In ECs 
co-seeded with CSCs, we found that integrin αvβ3 is 
necessary for BMX activation and that BMX is necessary 
for p130CAS activation whereas in ECs seeded in CM/
EC+CSC, αvβ3 is not necessary for BMX activation 
and BMX is not necessary for p130CAS activation. 
BMX, a cytoplasmic non-receptor tyrosine kinase, can 
activate signaling pathways that promote migration and 
angiogenesis as well as other signaling pathways [39, 40, 
42–46]; thus, the increased BMX activity downstream of 
activated integrin αvβ3 in the ECs co-seeded with CSCs 
could serve to amplify and diversify signaling.
The alterations in the actin cytoskeleton that 
occurred in ECs that contact CSCs suggest a pro-migratory 
phenotype, and co-seeding ECs with CSCs on laminin 
significantly increased EC migration towards bFGF as 
compared to that observed when the ECs were seeded on 
laminin in CM/EC+CSC. This increased migration was 
dependent on integrin αvβ3 on ECs and L1CAM on CSCs, 
supporting our hypothesis that the direct cell-cell contact 
promotes EC migration towards bFGF. The possibility 
that the migration was mediated by integrin αvβ3 binding 
to the laminin substrate was ruled out by the failure of 
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downregulation of β3 to significantly affect migration of 
the ECs seeded alone on laminin.
The current studies focus specifically on the effects 
of EC-CSC contact mediated by integrin αvβ3 on EC 
signaling and migration. To characterize this response, we 
focused on the 7-24 h time frame when cell-cell contact 
and directed migration were observed. We found distinct 
differences between the signals associated with migration 
Figure 6: Integrin αvβ3 is necessary for BMX activation and BMX is necessary for p130CAS activation in ECs 
contacting CSCs. ECs were seeded alone or with CSCs-(08387) as in Figure 2B. A-B. ECs were treated with BMX siRNA or control 
siRNA (48 h), followed by seeding as above and immunofluorescence for phos-p130CAS (Y234) (Alexa-488, green) and vWf (Alexa-647, 
magenta, marker of ECs). Confocal sections (0.5-µm apart) comprising the Z-stack are shown. White arrows denote phos-p130CAS and 
yellow arrows denote CSCs (vWf-negative) (A). The intensity of phos-p130CAS was determined in 15 representative cells as in Figure 
2E&2F and graphed as the fold-change. (B). C-F. ECs were treated with control siRNA (C) or integrin β3 siRNA (D) for 48 h, followed 
by seeding as above and immunofluorescence detection of phospho-BMX (pBMX) (Alexa-488 green) and vWf (Alexa-647, magenta, EC 
marker). Confocal sections (0.5-µm apart) comprising the Z-stack are shown. White arrows denote pBMX, yellow arrows denote CSCs 
(vWf-negative) and red asterisks denote ECs in phase contrast images (C,D). The intensity for pBMX was determined in 15 representative 
cells as in Figure 2E&2F and graphed as the fold-change. (F). Cells were harvested with Accutase, sorted for CD31, detergent lysed and 
immunoblotted as indicated (E). Statistics: B and F, two-sided exact Wilcoxon rank-sum tests.
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Figure 7: Administration of the RGD-peptide significantly reduces the proximity of Sox2-positive tumor cells to ECs, and 
BMX and p130CAS activation in ECs in an intracerebral xenograft model of GBM. A-D. LN-308 human GBM cells propagated 
in complete NBM in suspension were fluorescent-labeled for L1CAM (Alexa-594-red) (A); allowed to adhere to a monolayer of ECs after 
downregulation of L1CAM (B); mixed with ECs, plated on laminin-coated filters and allowed to migrate to bFGF as in Figure 5 (C), or L1CAM 
was downregulated and the migration assay repeated (D). E-K. LN-308 cells (100,000) were injected into the nude mouse brain, tumor allowed 
to establish for 55 days, and cyclic-RGD-peptide (90 mg/kg) or PBS were administered for 5 days (n=5 mice/group), followed by euthanasia 
at 2 h post-treatment and brain harvest. Sections double-labeled for vWf (Alexa-594, red) and either Sox2, pβ3-(Y759), phospho-BMX, or 
phospho-p130CAS (Y234) (Alexa-488, green), and DAPI nuclear staining (G). The mean Sox2-positive tumor cell distance from vWf-positive 
ECs (E), percent Sox2-positive tumor cells within 25-µm of a vWf-positive vessel (F), percent ECs positive for pβ3 (H), intensity of phospho-
BMX in tumor-associated ECs (I), intensity of phospho-p130CAS in tumor-associated ECs (J), and vessel surface area in the tumor (K) from 
RGD-peptide-treated mouse tumors relative to vehicle-treated control tumors. The intensity of phospho-BMX and phospho-p130CAS was 
calculated using FIJI (ImageJ) as in Figure 2 E&2F for vWf-positive blood vessels, and traced along their outer edge for each field taken at 40X 
magnification. Signal intensity was normalized by dividing the sum of the mean gray level by the area of the ECs in each blood vessel. Statistics: 
B-F, two-sided exact Wilcoxon rank-sum tests; and H-K, linear mixed regression model. Data graphed as the mean±SEM.
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of ECs induced by the direct interaction with CSCs and 
the signals induced by the soluble factors present in CM/
EC+CSC. These differences included the requirement for 
BMX for cell-contact induced signaling of migration, as 
evidenced by the downregulation of BMX and the use 
of a BMX inhibitor. These differences occurred in the 
context of some signals that were induced in both ECs that 
interacted directly CSCs and by soluble factors present 
in CM/EC+CSC. Such shared signaling may form the 
framework for the migratory behavior of the ECs whether 
or not they come into direct contact with the CSCs and will 
provide a basis for further investigation of, for example, 
the EC migratory polarity observed without CSCs, which 
most likely can be attributed to the chemotactic gradient 
of bFGF, and the induction of unpolarized migration in the 
7-24 h time frame of ECs that did not come into contact 
with CSCs.
Our in vivo animal studies indicate that treatment of 
an established GBM xenograft tumor with cyclic-RGD-
peptide significantly increased the mean distance of Sox2-
positive tumor cells from ECs as compared to controls. 
We also observed significant decreases in the percent of 
ECs with integrin αvβ3 activation, in BMX activation 
and p130CAS phosphorylation in ECs, and in vessel 
surface area in tumors from RGD-peptide-treated mice. 
A clinical trial of the cyclic-RGD-peptide (Cilengitide) in 
combination with standard chemo-radiation for patients 
with newly diagnosed GBM showed improvement of 
survival in a subset of patients [47]. Our current data 
indicate previously unrecognized mechanisms of action 
that may affect therapeutic responsiveness.
Prior studies that have shown that integrin αvβ3 
cooperation with bFGF promotes angiogenesis [9, 48–50] 
utilized models that do not take into account the effects 
of direct contact with perivascular CSCs or tumor cells 
on integrin αvβ3 signaling in the ECs. The current studies 
provide insights and also raise questions that are relevant 
to the ongoing development of strategies for utilization of 
targeted therapies, and most especially those directed to 
integrin αvβ3, L1CAM and ERK. In terms of regulation 
of signaling, for example, integrin αvβ3 cooperation with 
bFGF in confluent monolayers of ECs has been shown to 
be due to a complex formed between integrin αvβ3, the 
tetraspanin CD9, and the junctional adhesion molecule-A 
(JAMA) that upon bFGF stimulation releases JAMA 
thereby regulating ERK activation and migration [51] 
but it is not known whether a similar complex is formed 
in the context of EC-CSC contact. Others have reported 
that cell surface expression of L1CAM is regulated by 
endocytosis, through a process that requires Numb, a 
negative regulator of Notch signaling [52]. In some 
cancers (e.g., lung and breast cancer) activated ERK 
signaling drives alternative splicing of Numb resulting 
in expression of the Numb-E9 isoform that can enhance 
Notch signaling [53]. Also, activation of Notch signaling 
by its ligand Delta-like 4 promotes angiogenesis in tumors 
[54]. These data raise the intriguing question as to whether 
similar mechanisms affect cell surface L1CAM expression 
in GBM, and the intersection between Notch and ERK 
signaling and the cell interaction model that we propose 
in shaping tumor-associated angiogenesis. Although 
others have reported that, during metastasis, melanoma 
cells undergo transendothelial cell migration through a 
mechanism involving an interaction between integrin αvβ3 
on melanoma cells and L1CAM on ECs [55], it should 
be noted that GBM tumors rarely metastasize outside 
of the brain [2]. Finally, it is not known if the CSC-EC 
interaction also promotes survival and, if so, whether it 
does so through a mechanism akin to that observed on 
binding to an extracellular substrate [56, 57].
In summary, we have identified a previously 
unrecognized integrin αvβ3/bFGF initiated signaling event 
in the perivascular niche in GBM, involving EC contact 
with CSCs or tumor cells that requires BMX for activation 
of p130CAS and promotes chemotactic migration of ECs 
and thereby angiogenesis.
MATERIALS AND METHODS
Cells
Primary human normal brain ECs were purchased 
(Cell Systems, Kirkland, WA), cultured in EGM medium 
with growth factors (SingleQuots; Lonza, Basal, 
Switzerland), used in the first eight passages and von 
Willebrand factor (vWf) expression verified repeatedly, as 
described [30]. Primary human CSCs or NSTCs (08387) 
from four different GBM xenografts (08387, 3691, 3832, 
4302) were isolated and propagated as neurospheres 
in complete neural basal medium (NBM) (Life 
Technologies, Waltham, MA) without FBS, as described 
[58]. Re-authenticated LN-308 cells were received 
from Dr. Nicolas de Tribolet (Lausanne, Switzerland).
Re-authentication was performed by DNA profiling of 
8 highly polymorphic regions of Short Tandem Repeats 
using Nonaplex PCR at the Leibniz Institute DSMZ – 
German Collection of Microorganisms and Cell Cultures 
before use in these experiments. ECs were labeled with 
PKH26-red-fluorescent cell linker (Sigma, St. Louis, MO). 
Human astrocytes were purchased (Cell Systems) and 
cultured in DMEM with 10% FBS. U-118 MG GBM cells 
expressing L1LE or vector control (K1879) have been 
described previously [28]. The U-118/L1LE and U-118/
K1879 vector control cell lines were authenticated to the 
HTB-15 (U-118 MG) human ATCC cell line by DNA 
profiling of 17 short tandem repeat (STR) loci plus the 
gender determining loci at the ATCC.
Inhibitors and downregulation studies
Peptides (Peptides International, Louisville, KY) 
and PP2 (EMD Millipore) were purchased. Cyclic-
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RGD-peptide (Cilengitide) used in the mouse model was 
provided by Merck (Darmstadt, Germany). The FAK 
inhibitor PF573228 was purchased from Santa Cruz, and 
the BMX-Inhibitor-1 was purchased from EMD Millipore. 
Both were used at a final concentration of 1µM.
Small interfering ON-TARGETplus SMART 
pool RNA (siRNA) oligonucleotides were purchased 
(Dharmacon, Lafayette, CO). Pre-designed single 
target siRNA oligonucleotides for integrin β3 were 
purchased from Sigma (SASI_Hs01_00174222) and Life 
Technologies (s7582). Pre-designed single target siRNA 
oligonucleotides for L1CAM were purchased from 
Life Technologies (s8036, s8037, s8038). Pre-designed 
single target siRNA oligonucleotides for p130CAS were 
purchased from Life Technologies (s225161, s18373). 
Cells were transfected with oligonucleotides (HiPerfect, 
Qiagen, Hilden, Germany) and downregulation confirmed 
by immunoblotting [30, 59].
Antibodies
Antibodies were purchased: monoclonal antibodies, 
anti-integrin αvβ3, anti-integrin β3(CD61), and anti-
integrin α5β1 (Millipore, Billerica, MA), anti-human 
CD171 (L1CAM; BD Pharmingen, San Diego, CA), 
anti-integrin αvβ5 (R&D Systems, Minneapolis, MN), 
anti-actin, anti-β-tubulin, anti-phospho-ERK, and anti-
phospho-JNK (Santa Cruz, Dallas, TX), and anti-L1CAM 
UJ127 (GeneTex, Irvine, CA); rabbit antibodies, anti-
integrin β3 (Epitomics, Burlingame, CA), and anti-
phospho-FAK (Y397), anti-total FAK, anti-phospho-
BMX/Etk (Y40), anti-total BMX/Etk, and anti-total 
p130CAS (E1L9H) (Cell Signaling, Beverly, MA). 
Rabbit affinity purified phospho-specific anti-p130CAS 
(Y234) was generated using the following peptide: 
-AQPEQDE[pY]DIPRHL, corresponding to residues 227-
240 in human p130CAS, by 21st Century Biochemicals, 
Inc (Marlboro, MA) (SFigure 4).
Immunofluorescence
Cells were multi-labeled for immunofluorescence 
as described [30]. Confocal images were taken at 0.5µm 
steps (40X objective lens) using a Leica-TCS-SP5II-
AOBS confocal microscope (NDD detector).
Cell-cell adhesion
Adhesion assay buffer: (140 mM NaCl, 5.4 mM 
KCl, 5.56 mM D-glucose, 10 mM Hepes, pH 7.4, 1mM 
MgCl2, 100uM MnCl2, 1% BSA). Before cell seeding, 
the plate was blocked with 5% BSA (30 min). ECs were 
seeded overnight on collagen type I (MP Biomedicals) and 
the EC monolayer was confluent prior to beginning the 
assay. CSCs remaining attached to ECs were calculated 
based on a CSC standard curve (SFigure 1A).
Matrigel® EC network formation
Cells were seeded onto polymerized Matrigel® 
in complete NBM. Pictures (5X-magnification) from 
three independent assays were taken using a Zeiss A1 
microscope. CM from CSCs was prepared by seeding 
CSCs on laminin in complete NBM (72 h).
Motility assays
For the 2D assay, cell culture inserts and the 
Chemotaxis and Migration Tool 2.0 (Ibidi, Madison, WI) 
were used. Inserts were coated with 20 μg/ml laminin 
(R&D Systems). PKH26-red-fluorescent-ECs in EGM 
media were plated on one side of the insert, and GFP-
CSCs in complete NBM on the other side. Subsequently, 
the media was replaced with complete NBM, the insert 
removed, and live-imaging of cells into the gap initiated 
using a 10X objective lens and a motorized-stage (Leica-
DMI6000-ImageEM/Orca-R2-ImageProPlus). Manual 
Tracking (Image J) was used to trace EC paths into the 
500 µm gap [60]. ECs trajectories were projected onto 
the XY plane and the average velocity calculated for 
individual and total trajectories [60].
For analysis of CSCs/ECs migrating into the wound 
gap, an automated algorithm was generated by ImageIQ 
(Cleveland, OH) designed to batch process and analyze 
time-lapse, multi-channel stacks within ImagePro-
Plus-7.0.
For the Transwell® assay, cells were seeded on the 
upper filter surface (Transwell chambers, 3-µm pore, 
Corning), allowed to migrate, cells on the upper surface 
removed, and cells on the lower filter surface washed, 
fixed [11], photographed and counted in 5-10 fields with 
a 20X objective (Leica-DFC425C-QImaging-Q15729-
QCapturePro).
qRT-PCR
RNA was harvested, reverse transcribed, and 
quantitative PCR performed using the Syber Green 
system; levels of mRNA were normalized to GAPDH, as 
described [30].
Animal studies
Animal experiments were carried out as described 
[61] with the approval of the Institutional Animal Care 
and Use Committee at the University Hospital Zurich 
(Zurich, Switzerland). LN-308 cells (105 cells in 2-µl) 
were stereotactically injected into the striatum of 6-12 
week-old anesthetized athymic CD1 nude mice (Charles 
Rivers Laboratories, Wilmington, MA).
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Statistics
All statistical analyses were performed/overseen 
by the Biostatistician (ASN). The statistical test used is 
stated in the figure legend; a p value <0.05 was considered 
significant.
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